08 May 2026
Researchers from Queen’s University Belfast are investigating the role that the molecule RUNX1 plays in retinal fibrosis as part of efforts to develop new treatments for diabetic retinopathy.
The study, which is supported by Newmedica and Sight Research UK, will investigate whether targeting RUNX1 could help patients who do not respond to the standard treatment approach of anti-VEGF therapy.
The team will explore whether mRNA could be used to temporarily suppress RUNX1 activity.
Research project lead, Dr Michael O’Hare, noted that the aim of the research is to develop mRNA-encoded therapeutics.
He highlighted his gratitude for funding and support from Newmedica and Sight Research UK.
“It is essential in helping us to develop next-generation mRNA-encoded therapeutics and novel delivery systems that have potential as treatments not only for diabetic retinopathy, but for other ocular diseases as well,” O’Hare said.
Newmedica medical director, Nigel Kirkpatrick, shared: ‘We are pleased to be supporting this important project in partnership with Sight Research UK. We look forward to following the team’s progress.’
Comments (0)
You must be logged in to join the discussion. Log in